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Abstract. Runt-related transcription factor 3 (RUNX3) is 
known to function as a tumor suppressor in gastric cancer and 
other types of cancers, including hepatocellular carcinoma 
(HCC). However, its role has not been fully elucidated. In the 
present study, we aimed to evaluate the role of RUNX3 in 
HCC. We used the human HCC cell lines Hep3B, Huh7 and 
HLF; RUNX3 cDNA was introduced into Hep3B and Huh7 
cells, which were negative for endogenous RUNX3 expression, 
and RUNX3 siRNA was transfected into HLF cells, which 
were positive for endogenous RUNX3. We analyzed the 
expression of RUNX3 and multidrug resistance-associated 
protein (MRP) by immunoblotting. MTT assays were used to 
determine the effects of RUNX3 expression on 5-fluorouracil 
(5-FU) and cisplatin (CDDP) sensitivity. Finally, 23 HCC 
specimens resected from patients with HCC at Okayama 
University Hospital were analyzed, and correlations among 
immunohistochemical expression of RUNX3 protein and 
MRP protein were evaluated in these specimens. Exogenous 
RUNX3 expression reduced the expression of MRP1, MRP2, 
MRP3 and MRP5 in the RUNX3-negative cells, whereas 
knockdown of RUNX3 in the HLF cells stimulated the 
expression of these MRPs. An inverse correlation between 
RUNX3 and MRP expression was observed in the HCC tissues. 
Importantly, loss of RUNX3 expression contributed to 5-FU 
and CDDP resistance by inducing MRP expression. These 
data have important implications in the study of chemotherapy 
resistance in HCC.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common 
cancer and the third most frequent cause of cancer-related 
mortality worldwide (1,2). Although patients with early-stage 
HCC can receive curable treatment, the prognosis of patients 
with advanced disease is relatively poor. Drug resistance 
contributes to the poor prognosis in patients with advanced 
HCC, and elucidation of the molecular mechanisms under-
lying drug resistance would facilitate the development of more 
effective therapeutic strategies (3,4).
Drug efflux is a major molecular mechanism thought to 
affect drug resistance in patients with HCC. Increased drug 
efflux can decrease the accumulation of anticancer drugs (5). 
Multidrug resistance proteins (MRPs) are members of the 
ATP-binding cassette (ABC) transporter superfamily and are 
involved in drug efflux (6), contributing to the drug resistance 
observed in patients with HCC (5). Notably, MRPs are upregu-
lated in 5-fluorouracil (5-FU)-resistant cancer cells, and MRP5 
expression has been shown to influence 5-FU resistance in 
pancreatic carcinoma cells (7,8). Furthermore, various studies 
have shown that there is a significant association between 
MRPs and 5-FU sensitivity (9-12). Drug resistance to cisplatin 
(CDDP), another common anticancer agent used for HCC 
chemotherapy (13-16), is also mediated by MRPs (17-20).
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Human Runt-related transcription factor 3 (RUNX3), a 
tumor suppressor expressed in gastric cancers (21), regulates 
cell growth and apoptosis as a downstream effector of trans-
forming growth factor-β (TGF-β) signaling (22). RUNX3 was 
originally reported as a tumor suppressor in gastric cancer (21) 
and has been shown to function as a tumor suppressor in HCC 
as well (23,24). We and other researchers have reported that 
the protein and mRNA expression of RUNX3 are decreased 
in HCC and that loss of RUNX3 expression induces various 
effects in HCC, including prevention of apoptosis, induction of 
cancer stem cell-like changes, and promotion of the epithelial-
mesenchymal transition (EMT) (24,25). Moreover, RUNX3 
has been shown to regulate MRPs in pancreatic cancer (26). 
However, the mechanisms through which RUNX3 and MRPs 
may mediate drug resistance in HCC are not completely 
understood.
Therefore, in the present study, we assessed the relationship 
between RUNX3 and MRP expression in HCC. We also evalu-
ated the effects of RUNX3 re-expression on drug resistance to 
5-FU and CDDP in HCC.
Materials and methods
Cell lines and cell culture. The human HCC cell lines Hep3B, 
Huh7 and HLF were obtained from the American Type Culture 
Collection (ATCC; Manassas, VA, USA). The cells were 
maintained in Dulbecco's modified Eagle's medium (DMEM; 
Invitrogen, Carlsbad, CA, USA), supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 1% non-essential 
amino acids, 1% sodium pyruvate and 1% penicillin/strepto-
mycin solution (all from Sigma, St. Louis, MO, USA). The 
cells were cultured at 37˚C in an atmosphere containing 5% 
CO2 and 95% air. Cell growth was halted at subconfluency 
under restricted serum conditions with 0.1% dialyzed FBS for 
36 h before the experiments, if needed.
Ectopic RUNX3 expression. A human RUNX3 construct 
was obtained by reverse transcription-polymerase chain 
reaction (RT-PCR)-based cloning of the gene from normal 
human hepatocytes (Sanko Junyaku, Co., Ltd., Tokyo, Japan). 
Human RUNX3 and/or chloramphenicol acetyltransferase 
(CAT; mock) constructs were transfected into Hep3B, Huh7 
and HLF cells using FuGENE 6 transfection reagent (Roche 
Diagnostics, Basel, Switzerland). At least two independent 
transfections were performed for each cell line. The cells were 
incubated under serum-starved conditions for 24 h and used 
for the following experiments.
Immunoblot analysis. Cells were plated in 6-well plastic tissue 
culture dishes and grown to confluency. The cells were washed 
twice with cold phosphate-buffered saline (PBS) and lysed in 
150 µl of sample buffer [100 mNM Tris-HCl (pH 6.8), 10% 
glycerol, 4% sodium dodecyl sulfate (SDS), 1% bromophenol 
blue and 10% β-mercaptoethanol]. The samples were resolved 
by sodium dodecyl sulfate (SDS)-polyacrylamide gel elec-
trophoresis and transferred to Immobilon-P polyvinylidene 
difluoride membranes (Millipore Corporation, Bedford, MA, 
USA). The membranes were blocked using Tris-buffered 
saline with Tween-20 (TBS-T; Sigma) containing 5% bovine 
serum albumin for 1 h. The membranes were then incubated 
with antibodies against RUNX3, MRP1 and MRP2 (all from 
Abcam, Cambridge, MA), MRP3 (Sigma), MRP5 (Abcam), 
and β-actin (Sigma) overnight at 4˚C. The membranes were 
washed 3 times with TBS-T and probed with horseradish 
peroxidase-conjugated secondary antibodies before being 
developed with an enhanced chemiluminescence western blot-
ting detection system (Amersham Biosciences, Piscataway, NJ, 
USA).
MTT assay. Cell proliferation was assessed using 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assays. Briefly, cells were grown in 96-well plastic 
tissue culture dishes at a density of 1x104 cells/ml. After 24 h 
of quiescence, cells were cultured for the indicated period 
with or without 10% FBS. Then, 10 µl of MTT (5 mg/ml in 
PBS) was added to each well, and the cells were incubated for 
an additional 4 h at 37˚C. The purple-blue formazan precipi-
tate was dissolved in 100 µl of dimethyl sulfoxide (DMSO). 
Mitochondrial activity, which reflected cell viability, was 
evaluated by measuring the optical density at 570 nm on a 
microplate reader (Bio-Rad, Hercules, CA, USA).
To evaluate 5-FU and CDDP resistance, the cells were 
treated with various concentrations of 5-FU and/or CDDP 
for 72 h, and MTT assays were then performed as described 
above.
Gene silencing of RUNX3 with small interfering RNA (siRNA). 
RUNX3-expressing Hep3B and Huh7 cells were transfected 
with either scrambled negative control siRNA or RUNX3 
siRNA (Applied Biosystems, Foster City, CA, USA) using 
RNAiFect transfection reagent (Qiagen, Hilden, Germany). 
The cells were incubated for 24 h, and then serum starved for 
48 h. MTT assays were then performed.
HCC tissues and immunohistochemistry. A group of 
23 patients [18 men (age range, 52-78 years; average age 
65.1 years) and five women (age range, 55-74 years; average 
age, 65.8 years)] were included in the present study. Resected 
HCC tissues were obtained after receiving written informed 
consent that adhered to the stringent ethical criteria of the 
Okayama University Graduate School of Medicine, Dentistry 
and Pharmaceutical Sciences. Immunohistochemistry was 
performed on formalin-fixed paraffin-embedded sections 
prepared from the resected tissue. Sections were dewaxed and 
dehydrated; after rehydration, endogenous peroxidase activity 
was blocked for 30 min in a methanol solution containing 
0.3% hydrogen peroxide. Following antigen retrieval in citrate 
buffer, the sections were blocked again overnight at 4˚C. The 
sections were probed with anti-RUNX3 mouse monoclonal 
antibodies (ab40278), anti-MRP1 monoclonal antibodies 
(ab32574), anti-MRP2 monoclonal antibodies (ab15603) (all 
from Abcam), anti-MRP3 monoclonal antibodies (M6567; 
Sigma) and anti-MRP5 monoclonal antibodies (ab24107; 
Abcam). The primary antibody was detected using a bioti-
nylated anti-rabbit antibody or a biotinylated anti-mouse 
antibody (both from Dako Japan). The signal was ampli-
fied by avidin-biotin complex formation and was developed 
with diaminobenzidine, followed by dehydration in alcohol 
and xylene. The sections were then mounted and scored for 
RUNX3, MRP1, MRP2, MRP3 and MRP5 using a four-point 
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scale: 0, negative; 1, weak signal; 2, intermediate signal; and 
3, strong signal. All sections were scored independently by two 
observers without prior knowledge of the clinical background. 
All discrepancies in scoring were reviewed, and a consensus 
was reached. Statistical analyses were performed using JMP 
software (SAS Institute, Inc., Cary, NC, USA).
Gene expression profiling analysis in human HCC. To further 
investigate correlations between RUNX3 and MRP expression 
in HCC, publicly available HCC data sets were evaluated using 
Oncomine (http://www.oncomine.org). In brief, mRNA expres-
sion profiles for RUNX3, MRP1, MRP2, MRP3 and MRP5 
were evaluated using RUNX3/106_at, RUNX3/204197_s_at, 
RUNX3/204198_s_at, MRP1/34384_at, MRP2/206155_at, 
MRP3/209641_s_at, and MRP5/209380_s_at, respectively, in 
HCCs from the human liver data sets. Statistical analyses were 
performed using JMP software.
Results
Ectopic RUNX3 expression reduces MRP expression in HCC 
cell lines. Ectopic RUNX3 protein expression was regulated 
in 3 HCC cell lines exhibiting positive or negative endogenous 
RUNX3 expression (Hep3B, Huh7 and HLF cells) (24). RUNX3 
protein expression was detected by immunoblot analysis after 
transfection with the RUNX3 plasmid (Fig. 1). Hep3B, Huh7 
and HLF cells expressed MRP1, MRP2, MRP3 and MRP5. 
Ectopic RUNX3 protein expression generally decreased MRP 
expression levels in all 3 cell lines. Expression of MRP1, 
MRP2, MRP3 and MRP5 in the RUNX3-expressing Hep3B, 
Huh7 and HLF cells was weaker than that in the control 
CAT-expressing cells (Fig. 1).
Ectopic RUNX3 protein expression suppresses cell growth 
and increases 5-FU and CDDP sensitivity. Ectopic RUNX3 
expression suppressed cell growth in the Hep3B and Huh7 
cells compared with that in the control Hep3B and Huh7 
cells at 3 days after transfection (Fig. 2). Next, we analyzed 
the effects of RUNX3 on chemosensitivity in the RUNX3- or 
CAT (mock)-transfected Hep3B and Huh7 cells. RUNX3 
expression enhanced 5-FU sensitivity in both cell lines; the 
50% inhibitory concentration (IC50) of 5-FU decreased from 
8.16 to 4.84 nM and from 9.81 to 4.76 nM in the Hep3B and 
Huh7 cells, respectively (Fig. 2A). RUNX3 expression also 
enhanced CDDP sensitivity in both cell lines; the IC50 of CDDP 
decreased from 6.76 to 4.58 nM and from 9.28 to 4.57 nM in 
the Hep3B and Huh7 cells, respectively (Fig. 2B).
MRP expression is inversely correlated with RUNX3 expres-
sion in human HCC tissues. Twenty-three HCC tissue samples 
were available for comparison of MRP and RUNX3 protein 
expression by immunohistochemistry. Representative images 
of tissues with different levels of MRP1 expression, i.e., 
negative (score 0), weak signal (score 1), intermediate signal 
(score 2) and strong signal (score 3), are shown in Fig. 3A-D. 
Correlation analysis showed that high MRP expression scores 
were generally observed in tissues with low RUNX3 expres-
sion (Fig. 4).
Gene expression profiling analysis in human HCC. Lastly, we 
evaluated the effects of ectopic RUNX3 expression on MRPs 
in order to elucidate the mechanisms underlying RUNX3 
expression-induced chemosensitivity. We analyzed Oncomine 
data sets to examine the correlation between the expression of 
RUNX3 and MRPs. The results revealed that RUNX3 mRNA 
Figure 1. Immunoblot analysis. Eukaryotic expression constructs for CAT (mock) and RUNX3 were introduced into Hep3B, Huh7 and HLF cells. Cell lysates 
were collected 48 h after transfection. Immunoblot analysis was performed using antibodies against RUNX3, MRP1, MRP2, MRP3, MRP5 and β-actin. 
Immunoblotting for β-actin was used to verify equal loading of cellular proteins. Representative blots of more than 3 independent experiments are shown.
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Figure 2. Cell growth activity and sensitivity to chemotherapeutic agents. Hep3B and Huh7 cells were treated with the indicated concentrations of 5-FU (A) 
and CDDP (B) for 3 days. Cell viability was measured by MTT assay. All results are expressed as ratios relative to the value on day 1. Data represent the mean 
± SE of more than three independent experiments performed in triplicate.
Figure 3. Immunohistochemical analysis of MRP expression. The images show the immunohistochemical staining of MRP1 (A, score of 0; B, score of 1; 
C, score of 2; and D, score of 3). Scale bar, 100 µm.
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expression was inversely correlated with MRP1, MRP2, 
MRP3 and MRP5 mRNA expression (MRP1, r=-0.6007, 
P=0.1538; MRP2, r=-0.55729, P<0.05; MRP3, r=-0.53741, 
P<0.05; MRP5, r=-0.36607, P<0.05; Fig. 5).
Figure 4. Correlation between RUNX3 expression and (A) MRP1, (B) MRP2, (C) MRP3 and (D) MRP5 expression scores in human HCC tissues. Plots of MRP 
expression scores are shown compared with RUNX3 expression scores.
Figure 5. Correlation between RUNX3 and MRP expression in human HCC data sets. The correlation between RUNX3 and MRP expression was analyzed 
using publically available microarray data sets (http://www.oncomine.org). The correlation coefficients and P-values of the relationships among RUNX3, 
MRP1, MRP2, MRP3 and MRP5 expression are shown. The 95% tolerance ellipses for pairs of variables have been plotted.
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Discussion
Chemoresistance is a major challenge encountered during 
the therapeutic treatment of HCC. In the present study, we 
evaluated the relationship between RUNX3 expression and 
chemosensitivity in HCC. RUNX3 was found to act as a tumor 
suppressor in HCC, consistent with previous studies showing 
that RUNX3 is frequently lost in HCC (23,27-29) and that loss 
of RUNX3 contributes to the malignant transformation of 
HCC (23-25).
In a previous study of pancreatic cancer, we reported that 
the RUNX3 expression status affects gemcitabine sensitivity 
by attenuating MRP expression (26). Therefore, we hypothe-
sized that RUNX3 expression may influence chemosensitivity 
in HCC. Drug resistance can be induced by several cellular 
processes. For example, MRPs mediate drug efflux, which 
decreases the accumulation of drugs within cancer cells. In 
the present study, we found that MRP expression generally 
decreased following ectopic expression of RUNX3 in all 
3 HCC cell lines examined. Moreover, these cells exhibited 
higher chemosensitivity to 5-FU and CDDP than control cells, 
further supporting the role of MRPs in drug resistance in these 
cells.
Consistent with a previous study in pancreatic cancer, we 
found that RUNX3 blocked MRP expression in HCC cells. 
Moreover, MRP expression varied in HCC tissues and was 
positively correlated with RUNX3 protein expression. Since 
the number of HCC tissues in the present study was relatively 
small, we also assessed the relationship between MRPs 
and RUNX3 expression using the Oncomine database; this 
analysis further supported the positive correlation between 
RUNX3 and MRP expression. These results indicated that 
RUNX3 expression may regulate MRP expression. Notably, 
RUNX3 expression has been shown to sensitize gastric cancer 
cells to chemotherapeutic drugs by downregulating MRP1 
through inhibition of MRP1 promoter activity (30). Thus, our 
findings suggest that RUNX3 may regulate MRP expression 
by inhibiting promoter activity in HCC cells and that targeting 
of RUNX3 and related signaling molecules may be a potential 
treatment modality for HCC.
Although we assessed the relationship between MRPs and 
RUNX3 expression in the present study, other factors have 
also been implicated in 5-FU and CDDP resistance. Multidrug 
resistance 1 (MDR1/ABCB1) and other ABCB transporters 
are also involved in the resistance against 5-FU (10,31,32). 
CDDP resistance is established via a multifactorial mecha-
nism including drug efflux and drug inactivation (33-35). In 
the present study, we did not evaluate the effects of RUNX3 
protein expression on these mechanisms; thus, further studies 
are necessary.
In conclusion, the loss of RUNX3 expression may upregu-
late MRP expression, thereby contributing to 5-FU and CDDP 
resistance in patients with HCC. Moreover, re-expression of 
RUNX3 downregulated MRP expression and resensitized 
HCC cells to 5-FU and CDDP.
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